Production (Stage)
Connect Biopharma Holdings Limited
CNTB
$0.9799
$0.02993.15%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -- | -- | -- | 60.01% | 47.78% |
| Total Depreciation and Amortization | -- | -- | -- | -42.67% | -40.85% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -- | -- | -- | -26.41% | -42.85% |
| Change in Net Operating Assets | -- | -- | -- | 1,607.35% | 470.80% |
| Cash from Operations | -- | -- | -- | 74.74% | 65.20% |
| Capital Expenditure | -- | -- | -- | 99.68% | 101.67% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | 167.06% | 306.86% |
| Cash from Investing | -- | -- | -- | 212.77% | 285.39% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | 124.10% | 114.89% |
| Issuance of Common Stock | -- | -- | -- | 45.67% | -91.88% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -- | -- | -- | 160.13% | 165.76% |
| Foreign Exchange rate Adjustments | -- | -- | -- | 94.75% | 88.66% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -- | -- | -- | 144.48% | 124.79% |